{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T04:27:57Z","timestamp":1742358477046,"version":"3.40.1"},"reference-count":55,"publisher":"Index Copernicus","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Otolaryngol Pol"],"published-print":{"date-parts":[[2025,3,18]]},"abstract":"<jats:p>&lt;b&gt;Introduction:&lt;\/b&gt; The primary treatment method for T2 immune response-related airway inflammations, such as eosinophilic inflammation, is topical glucocorticosteroid therapy. However, its effectiveness is limited by the challenge of drug penetration into the perinasal cavity. The introduction of a new generation of pulsating nebulizers has partially addressed this issue. Pulsating nebulizers (vibrating aerosol) enhance the penetration of nebulized medication into the paranasal sinuses, thereby opening a new therapeutic option for the treatment of chronic sinusitis. Consequently, a new regulatory indication has been approved for the use of budesonide in chronic rhinosinusitis with nasal polyps. &lt;br&gt;&lt;br&gt;&lt;b&gt;Aim:&lt;\/b&gt; The aim of the study was to compare the aerodynamic particle size distribution (APSD) of the dispersed suspensions of the test drug (TD) and the reference drug (RD) administered using the PARI SINUS2 nebulizer system, consisting of the PARI LC SPRINT SINUS nebulizer and the PARI SINUS2 compressor &lt;br&gt;&lt;br&gt;&lt;b&gt;Material and methods:&lt;\/b&gt; Comparison of the APSD of the dispersed suspensions of the TD and the RD administered using the PARI SINUS2 nebulizer system. Twelve nebulizations of each formulation were tested using six PARI SINUS2 nebulizer systems, with two repetitions per system. The methods were review of studies and own research. The APSD study was conducted using a next-generation impactor (NGI) and a laser diffraction spectrometer after nebulization of 2 mL suspensions of TD and RD via the PARI SINUS2 nebulizer system. Statistical analyses included descriptive statistics as well as 90% and 95% confidence intervals for the difference in means and the ratio of means of the examined parameters. &lt;br&gt;&lt;br&gt;&lt;b&gt;Results:&lt;\/b&gt; The TD was well-suited to the nebulization procedure. Both formulations (TD and RD) exhibited significant variability in the aerosol droplet distribution at different levels of the NGI cascade impactor. In the case of TD, larger droplets were more easily generated, which promoted deposition of the drug at the upper levels of the impactor. The equivalence of the two forms of budesonide, RD and TD, in the treatment of chronic rhinosinusitis with nasal polyps using a pulsating nebulizer was demonstrated. These indications were acknowledged by the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPLWMiPB) and added to the Product Information of TD. &lt;br&gt;&lt;br&gt;&lt;b&gt;Conclusions:&lt;\/b&gt; Both budesonide formulations were effective. Budesonide administered via vibrational nebulization is effective in the treatment of chronic rhinosinusitis with nasal polyps.<\/jats:p>","DOI":"10.5604\/01.3001.0055.0005","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T12:36:37Z","timestamp":1741350997000},"page":"29-38","source":"Crossref","is-referenced-by-count":0,"title":["Enhanced Therapeutic Options for Budesonide Nebulisation via Pulsating Nebuliser in Upper Respiratory Tract Diseases"],"prefix":"10.5604","volume":"79","author":[{"given":"Boles\u0142aw","family":"Samoli\u0144ski","sequence":"first","affiliation":[{"name":"Department of Public and Environmental Health, Division of Environmental Hazard Prevention, Allergology, and Immunology, Medical University of Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konrad","family":"Furma\u0144czyk","sequence":"additional","affiliation":[{"name":"Department of Public and Environmental Health, Division of Environmental Hazard Prevention, Allergology, and Immunology, Medical University of Warsaw, Poland, Institute of Technical Informatics, Warsaw University of Life Sciences, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Emeryk","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pulmonology, and Rheumatology, University Children's Hospital in Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz R.","family":"Sosnowski","sequence":"additional","affiliation":[{"name":"Department of Distributed Systems Engineering, Faculty of Chemical and Process Engineering, Warsaw University of Technology, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Bijo\u015b","sequence":"additional","affiliation":[{"name":"Medical Division, Teva Pharmaceuticals Poland Sp. z o.o., Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3689","reference":[{"key":"627728r1","unstructured":"Nebbud 0.5 mg\/ml, ChPL, https:\/\/rejestry.ezdrowie.gov.pl\/rpl\/search\/public (11.07.2024)."},{"key":"627728r2","doi-asserted-by":"crossref","unstructured":"Fokkens W., Lund V.J., Hopkins C. et al.: European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology., 2020; 58(Suppl S29): 1\u2013464. doi:10.4193\/Rhin20.600.","DOI":"10.4193\/Rhin20.600"},{"key":"627728r3","unstructured":"Samoli\u0144ski B., Zawisza E., \u015awierczy\u0144ski Z.: Long term study of aerosol corticosteroid treatment (Syntaris) in nasal polyps. Pneumonol. Alergol. Pol., 1992;60(supl.2): 153\u2013156."},{"key":"627728r4","unstructured":"Samoli\u0144ski B., Zawisza E., J\u0119kot R., \u015awierczy\u0144ski Z.: Kliniczne aspekty miejscowej sterydoterapii polip\u00f3w nosa przy u\u017cyciu preparatu Syntaris Nasal Spray.Otolaryngologia Polska, 1986; 2: 301\u2013303."},{"key":"627728r5","unstructured":"Holopainen E., Grahne B., Malmberg H., M\u00e4kinien J., Lindqvist N.: Budezonidein the treatment of nasal polyposis. Eur J Respir Dis Suppl., 1982; 122: 221\u2013228."},{"key":"627728r6","doi-asserted-by":"crossref","unstructured":"Moller W., Lubbers C., Munzing W., Canis M.: Pulsating airflow and drug deliveryto paranasal sinuses. Curr Opin Otolaryngol Head Neck Surg., 2011; 19: 48\u201353.","DOI":"10.1097\/MOO.0b013e3283420f39"},{"key":"627728r7","doi-asserted-by":"crossref","unstructured":"Alobid I., Ben\u00edtez P., Cardel\u00fas S. et al.: Oral plus nasal corticosteroids improvesmell, nasal congestion, and inflammation in sino-nasal polyposis. Laryngoscope., 2014; 124(1): 50\u201356.","DOI":"10.1002\/lary.24330"},{"key":"627728r8","doi-asserted-by":"crossref","unstructured":"Alobid I., Benitez P., Valero A. et al.: Oral and intranasal steroid treatmentsimprove nasal patency and paradoxically increase nasal nitric oxide in patientswith severe nasal polyposis. Rhinology., 2012; 50(2): 171\u2013177.","DOI":"10.4193\/Rhin10.140"},{"key":"627728r9","unstructured":"Alobid I., Benitez P., Pujols L. et al.: Severe nasal polyposis and its impact onquality of life. The effect of a short course of oral steroids followed by long-termintranasal steroid treatment. Rhinology., 2006; 44(1): 8\u201313."},{"key":"627728r10","doi-asserted-by":"crossref","unstructured":"Ben\u00edtez P., Alobid I., de Haro J. et al.: A short course of oral prednisone followed by intranasal budezonide is an effective treatment of severe nasal polyps.Laryngoscope., 2006; 116(5): 770\u2013775.","DOI":"10.1097\/01.mlg.0000205218.37514.0f"},{"key":"627728r11","doi-asserted-by":"crossref","unstructured":"Berggren F., Johansson L.: Cost effectiveness of nasal budezonide versus surgical treatment for nasal polyps. Pharmacoeconomics., 2003; 21(5): 351\u2013356.","DOI":"10.2165\/00019053-200321050-00006"},{"key":"627728r12","doi-asserted-by":"crossref","unstructured":"Blomqvist E.H., Lundblad L., Bergstedt H., Stj\u00e4rne P.: A randomized prospective study comparing medical and medical-surgical treatment of nasal polyposis by CT. Acta Otolaryngol., 2009; 129(5): 545\u2013549.","DOI":"10.1080\/00016480802298089"},{"key":"627728r13","unstructured":"Filiaci F., Passali D., Puxeddu R., Schrewelius C.: A randomized controlled trialshowing efficacy of once daily intranasal budezonide in nasal polyposis. Rhinology., 2000; 38(4): 185\u2013190."},{"key":"627728r14","doi-asserted-by":"crossref","unstructured":"Jankowski R., Schrewelius C., Bonfils P. et al.: Efficacy and tolerability of budezonide aqueous nasal spray treatment in patients with nasal polyps. ArchOtolaryngol Head Neck Surg., 2001; 127(4): 447\u2013452.","DOI":"10.1001\/archotol.127.4.447"},{"key":"627728r15","doi-asserted-by":"crossref","unstructured":"Johansson L., Holmberg K., Mel\u00e9n I., Stierna P., Bende M.: Sensitivity of a newgrading system for studying nasal polyps with the potential to detect earlychanges in polyp size after treatment with a topical corticosteroid (budezonide). Acta Otolaryngol., 2002; 122(1): 49\u201353.","DOI":"10.1080\/00016480252775733"},{"key":"627728r16","doi-asserted-by":"crossref","unstructured":"Thamboo A., Manji J., Szeitz A. et al.: The safety and efficacy of short--term budezonide delivered via mucosal atomization device for chronicrhinosinusitis without nasal polyposis. Int Forum Allergy Rhinol., 2014;4(5): 397\u2013402.","DOI":"10.1002\/alr.21280"},{"key":"627728r17","doi-asserted-by":"crossref","unstructured":"Smith K.A., Rudmik L.: Impact of continued medical therapy in patients withrefractory chronic rhinosinusitis. Int Forum Allergy Rhinol. 2014; 4(1): 34\u201338.doi: 10.1002\/alr.21238.","DOI":"10.1002\/alr.21238"},{"key":"627728r18","doi-asserted-by":"crossref","unstructured":"Snidvongs K., Kalish L., Sacks R. et al.: Sinus surgery and delivery method influence the effectiveness of topical corticosteroids for chronic rhinosinusitis:systematic review and meta-analysis. Am J Rhinol Allergy., 2013; 27(3): 221\u2013 233 doi: 10.2500\/ajra.2013.27.3880.","DOI":"10.2500\/ajra.2013.27.3880"},{"key":"627728r19","doi-asserted-by":"crossref","unstructured":"Tait S., Kallogjeri D., Suko J. et al.: Effect of Budesonide Added to Large-Volume,Low-pressure Saline Sinus Irrigation for Chronic Rhinosinusitis: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg., 2018; 144(7): 605\u2013612.","DOI":"10.1001\/jamaoto.2018.0667"},{"key":"627728r20","doi-asserted-by":"crossref","unstructured":"Young L.C., Stow N.W., Zhou L., Douglas R.G.: Efficacy of medical therapy intreatment of chronic rhinosinusitis. Allergy Rhinol (Providence)., 2012; 3(1):e8\u2013e12. doi: 10.2500\/ar.2012.3.0027.","DOI":"10.2500\/ar.2012.3.0027"},{"key":"627728r21","doi-asserted-by":"crossref","unstructured":"Fowler J., Rotenberg B.W., Sowerby L.J.: The subtle nuances of intranasal corticosteroids. J Otolaryngol Head Neck Surg., 2021; 50(1): 18.","DOI":"10.1186\/s40463-020-00480-z"},{"key":"627728r22","unstructured":"Filiaci F., Passali D., Puxeddu R., Schrewelius C.: A randomized controlledtrial showing efficacy of once daily intranasal budezonide in nasal polyposis.Rhinology., 2000; 38: 185\u2013190."},{"key":"627728r23","doi-asserted-by":"crossref","unstructured":"Gulati S.K., Sharma K., Shergill G.K., Kumar R.: Prophylactic budezonidenasal spray after polypectomy. Indian J Otolaryngol Head Neck Surg., 2001;53: 207\u2013209.","DOI":"10.1007\/BF03028555"},{"key":"627728r24","unstructured":"Lund V.J., Black J.H., Szabo L.Z., Schrewelius C., Akerlund A.: Efficacy and tolerability of budezonide aqueous nasal spray in chronic rhinosinusitis patients.Rhinology., 2004; 42: 57\u201362."},{"key":"627728r25","doi-asserted-by":"crossref","unstructured":"Wang C. Lou H., Xiangdong W. et al.: Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps.J Allergy Clin Immunol., 2015; 135(4): 922\u2013929.e6. doi: 10.1016\/j.jaci.2014.10.018.","DOI":"10.1016\/j.jaci.2014.10.018"},{"key":"627728r26","unstructured":"PARI, PARI SINUS2. https:\/\/www.pari.com\/int\/products\/nose-and-nasal-sinuses\/pari-sinus2-int\/ (11.07.2024)."},{"key":"627728r27","unstructured":"Dr. Arun Kumar, Study No.: WF009 Feasibility study for the nebulization of Nebbud (Budezonide 1mg\/2ml; TEVA) inhalation formulation with PARI SINUS2."},{"key":"627728r28","unstructured":"Instrukcja dla Lekarza. https:\/\/tevamed.pl\/tevamed\/Materialy_edukacyjne\/Nebbud_EDU_HCP.pdf (3.12.2024)."},{"key":"627728r29","unstructured":"R-projekt. www.r-projekt.org (11.07.2024)."},{"key":"627728r30","unstructured":"WF009 Feasibility study for the nebulization of Nebbud (Budezonide 1mg\/2ml;TEVA) inhalation formulation with PARI SINUS2."},{"key":"627728r31","doi-asserted-by":"crossref","unstructured":"Fieller E.C.: The biological standardization of Insulin. Suppl to J R Statist Soc.,1940; 7: 1\u201364.","DOI":"10.2307\/2983630"},{"key":"627728r32","unstructured":"EMA CPMPEWP415100 Rev. 1_en. https:\/\/www.ema.europa.eu\/en\/requirements-demonstrating-therapeutic-equivalence-between-orally-inhaledproducts-oip-asthma-chronic-obstructive-pulmonary-disease-copd-scientific-guideline (11.07.2024)."},{"key":"627728r33","doi-asserted-by":"crossref","unstructured":"Zhang Y., Lou H., Wang Y. et al.: Comparison of Corticosteroids by 3 Approaches to the Treatment of Chronic Rhinosinusitis With Nasal Polyps. AllergyAsthma Immunol Res., 2019; 11(4): 482\u2013497.","DOI":"10.4168\/aair.2019.11.4.482"},{"key":"627728r34","unstructured":"Betlejewski S.: Fizjologia. W: Alergiczne i niealergiczne nie\u017cyty nosa, red. B.Samoli\u0144ski, M. \u015aliwi\u0144ska-Kowalska. Mediton, \u0141\u00f3d\u017a 2003, 19\u201323."},{"key":"627728r35","unstructured":"Choroby nosa i zatok przynosowych, red. A. Krzeski, G. Janczewski. Sanmedia, Warszawa 1997, 43\u201350."},{"key":"627728r36","unstructured":"Samoli\u0144ski B., Arcimowicz M.: Patofizjologia nie\u017cyt\u00f3w nosa. W: Nie\u017cyty nosa,red. B. Samoli\u0144ski, G. Janczewski. Scholar, Warszawa 2000, 9\u201336."},{"key":"627728r37","doi-asserted-by":"crossref","unstructured":"Schwab J., Zenkel M.: Filtration of particles in the Human Nose. Laryngoscope., 1998; 108: 120\u2013124.","DOI":"10.1097\/00005537-199801000-00023"},{"key":"627728r38","unstructured":"Samoli\u0144ski B., Arcimowicz M.: Polskie Standardy Leczenia Nie\u017cyt\u00f3w Nosa(PoSL eNN). Alergol Pol., 2013; S1: 25\u201327."},{"key":"627728r39","doi-asserted-by":"crossref","unstructured":"Stammberger H.: Surgical treatment of nasal polyps: past, present and future.Allergy., 1999; 54: 7\u201311.","DOI":"10.1111\/j.1398-9995.1999.tb05031.x"},{"key":"627728r40","doi-asserted-by":"crossref","unstructured":"Moller W., Schuschnig U., Bartenstein P. et al.: Drug delivery to paranasal sinusesusing pulsating aerosols. J Aerosol Med Pulm Drug Deliv., 2014; 27: 255\u2013263.","DOI":"10.1089\/jamp.2013.1071"},{"key":"627728r41","doi-asserted-by":"crossref","unstructured":"Frank D.O., Kimbell J.S., Pawar S., Rhee J.S.: Effects of anatomy and particle sizeon nasal sprays and nebulizers. Otolaryngol Head Neck Surg., 2012; 146: 313\u2013319.","DOI":"10.1177\/0194599811427519"},{"key":"627728r42","doi-asserted-by":"crossref","unstructured":"Suman J.D., Laube B.L., Dalby R.: Comparison of nasal deposition and clearance of aerosol generated by nebulizer and an aqueous spray pump. PharmRes., 1999; 16: 1648\u20131652.","DOI":"10.1023\/A:1011933410898"},{"key":"627728r43","doi-asserted-by":"crossref","unstructured":"Kundoor V., Dalby R.N.: Assessment of nasal spray deposition pattern in a silicone human nose model using a color-based method. Pharm Res., 2010; 27: 30\u201336.","DOI":"10.1007\/s11095-009-0002-4"},{"key":"627728r44","doi-asserted-by":"crossref","unstructured":"Hilton C., Wiedmann T., St Martin M. et al.: Differential deposition of aerosols in themaxillary sinus of human cadavers by particle size. Am J Rhinol., 2008; 22: 395\u2013398.","DOI":"10.2500\/ajr.2008.22.3192"},{"key":"627728r45","doi-asserted-by":"crossref","unstructured":"Moller W., Schuschnig U., Celik G. et al.: Topical drug delivery in chronic rhinosinusitis patients before and after sinus surgery using pulsating aerosols.PloS One., 2013; 8: e74991.","DOI":"10.1371\/journal.pone.0074991"},{"key":"627728r46","doi-asserted-by":"crossref","unstructured":"Nair A., Vaidyanathan S., Clearie K.: Steroid sparing effects of intranasal corticosteroids in asthma and allergic rhinitis. Allergy., 2010; 65: 359\u2013367.","DOI":"10.1111\/j.1398-9995.2009.02187.x"},{"key":"627728r47","doi-asserted-by":"crossref","unstructured":"Lou H., Wang C., Zhang L.: Steroid Transnasal Nebulization In The TreatmentOf Chronic Rhinosinusitis. Curr Opin Allergy Clin Immunol., 2016; 16(1): 39\u201344.","DOI":"10.1097\/ACI.0000000000000230"},{"key":"627728r48","unstructured":"Lou H., Wang C., Zhang L.: The efficacy and safety of nasal nebulization ofbudezonide inhalation suspension compared with oral hormone therapy inchronic rhinosinusitis with nasal polyps. J Clin Otorhinolaryngology HeadNeck Surg (China)., 2015; 29(9): 792\u2013796."},{"key":"627728r49","unstructured":"Wang C., Luo H., Lou W., Zhang L.: The efficacy and safety of a short courseof budezonide inhalation suspension via transnasal nebulization in chronicrhinosinusitis with nasal polyps. J Clin Otorhinolaryngology Head Neck Surg(China)., 2012; 26(8): 347\u2013350."},{"key":"627728r50","doi-asserted-by":"crossref","unstructured":"Zheng P., Zhang Y., Zhang S., Liu G., Wang J.: Nasal nebulization inhalation of budezonide for chronic rhinosinusitis with nasal polyps A protocol for systematic review andmeta-analysis. Medicine., 2020; 99(22): e20354. doi: 10.1097\/MD.0000000000020354.","DOI":"10.1097\/MD.0000000000020354"},{"key":"627728r51","unstructured":"Moller W., Schuschnig U., Meyer G., Mentzel H., Keller M.: Ventilation anddrug delivery to the paranasal sinuses: studies in a nasal cast using pulsatingairflow. Rhinology., 2008; 46: 213\u2013220."},{"key":"627728r52","doi-asserted-by":"crossref","unstructured":"Moller W., Schuschnig W., Khadem Saba G. et al.: Pulsating aerosols for drugdelivery to the sinuses in healthy volunteers. Otolaryngol. Head Neck Surg.,2020; 142: 382\u2013388.","DOI":"10.1016\/j.otohns.2009.12.028"},{"key":"627728r53","doi-asserted-by":"crossref","unstructured":"Sosnowski T.R., Florkiewicz E., Sosnowski K.: Use of process intensificationconcepts for targeted delivery of inhaled aerosolized medicines. Chem. Eng.Process., 2024; 203: 109902.","DOI":"10.1016\/j.cep.2024.109902"},{"key":"627728r54","doi-asserted-by":"crossref","unstructured":"Zhang Y., Lou H., Wang Y. et al.: Comparison of Corticosteroids by 3 Approaches to the Treatment of Chronic Rhinosinusitis With Nasal Polyps. AllergyAsthma Immunol Res., 2019; 11(4): 482\u2013497.","DOI":"10.4168\/aair.2019.11.4.482"},{"key":"627728r55","doi-asserted-by":"crossref","unstructured":"M\u00f6ller W., Schuschnig U., Meyer G. et al.: Visualization of human sinus ventilation by radioactive Krypton using the PARI SINUS pulsating system. W:Respiratory Drug Delivery Europe, red. R.N. Dalby, P.R. Byron, J. Peart, J.D.Suman. Virginia Commonwealth University, Paris 2007, 275\u2013278.","DOI":"10.1016\/S1569-1993(07)60047-2"}],"container-title":["Otolaryngologia Polska"],"original-title":[],"link":[{"URL":"https:\/\/otolaryngologypl.com\/gicid\/pdf\/01.3001.0055.0005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/otolaryngologypl.com\/gicid\/pdf\/01.3001.0055.0005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T13:28:51Z","timestamp":1742304531000},"score":1,"resource":{"primary":{"URL":"https:\/\/otolaryngologypl.com\/gicid\/01.3001.0055.0005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,18]]}},"URL":"https:\/\/doi.org\/10.5604\/01.3001.0055.0005","relation":{},"ISSN":["0030-6657","2300-8423"],"issn-type":[{"type":"print","value":"0030-6657"},{"type":"electronic","value":"2300-8423"}],"subject":[],"published":{"date-parts":[[2025,3,18]]}}}